APUS Apimeds Pharmaceuticals US, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $0 on the open market.
Recent APUS insider trades
- May 14, 2025: Kim Christopher bought 27,500 shares ($50.4K)
- May 12, 2025: Koo Jakap bought 28,500 shares ($56.7K)
5%+ owners
- Apimeds Inc.: 34.3% (Schedule 13D/A, filed May 7, 2026)
- Ayrton Capital LLC: 10.0% (Schedule 13G, filed Feb 11, 2026)